ArticleCancer immunology, immunotherapy : CII2021

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.

Sarah B Reusing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.